Top

Published in:

01-09-2019 | Urothelial Cancer | Original Article

Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder

Authors: Maria Del Carmen Rodriguez Pena, Alcides Chaux, Marie-Lisa Eich, Aline C. Tregnago, Diana Taheri, Walaa Borhan, Rajni Sharma, M. Katayoon Rezaei, George J. Netto

Published in: Virchows Archiv | Issue 3/2019

Abstract

The Cancer Genome Atlas project introduced genomic taxonomy of basal and luminal molecular subtypes in muscle invasive bladder cancer. Fewer studies have addressed the molecular classification in non-muscle invasive bladder cancer (NMIBC). Our aim is to assess the applicability of the proposed phenotypic classification for NMIBC. Three TMAs were constructed from 193 TURBT specimens of 60 bladder cancer patients treated at one of the authors’ institutions (1998–2008). Follow-up data on recurrence, grade, or stage progression was obtained. Immunohistochemistry was performed using an automated Ventana System for markers indicative of luminal (GATA3, CK20, ER, Uroplakin II, and HER2/neu) and basal (CK5/6 and CD44) phenotype. Marker expression was evaluated by 3 urologic pathologists. Using unadjusted logistic regression, we found significant association between tumor recurrence at next biopsy and CD44 expression (OR = 2.51, P = 0.03), tumor recurrence at any subsequent biopsy and ER expression (OR = 0.24, P = 0.04), and tumor grade progression at any subsequent biopsy and HER2/neu expression (OR = 0.24, P = 0.04). After adjusting for pathologic stage, we found a significant association between CK5/6 expression and tumor stage progression at either next or any subsequent biopsy (OR = 0.94, P = 0.006; and OR = 0.97, P = 0.02, respectively). Our findings suggest that individual immunohistochemical markers may be of value as prognostic factors in NMIBC.

Available only for authorised users

Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551 CrossRefPubMed

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447–461. https://doi.org/10.1016/j.eururo.2016.05.041 CrossRefPubMed

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909–1920. https://doi.org/10.1016/s0140-6736(16)00561-4 CrossRefPubMedPubMedCentral

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JA, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18:312–322. https://doi.org/10.1016/s1470-2045(17)30065-7 CrossRefPubMed

Sjodahl G, Lovgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, Aine M, Eriksson P, Mansson W, Lindgren D, Ferno M, Liedberg F, Hoglund M (2013) Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol 183:681–691. https://doi.org/10.1016/j.ajpath.2013.05.013 CrossRefPubMed

Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315–322. https://doi.org/10.1038/nature12965 CrossRef

Inamura K (2018) Bladder cancer: new insights into its molecular pathology. Cancers 10:100. https://doi.org/10.3390/cancers10040100 CrossRefPubMedCentral

McConkey DJ, Choi W, Dinney CP (2015) Genetic subtypes of invasive bladder cancer. Curr Opin Urol 25:449–458. https://doi.org/10.1097/MOU.0000000000000200 CrossRefPubMed

Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152–165. https://doi.org/10.1016/j.ccr.2014.01.009 CrossRefPubMedPubMedCentral

10.

Robertson AG, Kim J, H A-A, J B, G G, AD C, T H, PW L, KA H, R A, MAA C, EA G, RS K, DA G, SA S, F S-V, DE H, BA C, VE R, X S, B d SC, VS C, KL M, S S, CS P, Y L, LJ K, J Z, C C, AI O, S B, KM L, TM L, CJ W, N S, G G, M M, GB M, DJ MC, Research Network TCGA, JN W, DJ K, SP L (2017) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171:540–556.e525. https://doi.org/10.1016/j.cell.2017.09.007 CrossRefPubMedPubMedCentral

11.

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, Segersten U, Aine M, Hoglund M, Birkenkamp-Demtroder K, Fristrup N, Borre M, Hartmann A, Stohr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmstrom PU, Malats N, Real FX, Zwarthoff EC, Orntoft TF, Dyrskjot L (2016) Comprehensive transcriptional analysis of early-stage urothelial carcinoma cancer cell. 30:27–42. https://doi.org/10.1016/j.ccell.2016.05.004

12.

Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A, Consortium B (2017) In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Arch 470:267–274. https://doi.org/10.1007/s00428-017-2064-8 CrossRefPubMed

13.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31:3997–4013. https://doi.org/10.1200/jco.2013.50.9984 CrossRef

14.

Abrahao-Machado LF, Scapulatempo-Neto C (2016) HER2 testing in gastric cancer: an update. World J Gastroenterol 22:4619–4625. https://doi.org/10.3748/wjg.v22.i19.4619 CrossRefPubMedPubMedCentral

15.

Raspollini MR, Luque RJ, Menendez CL, Bollito E, Brunelli M, Martignoni G, Montironi R, Cheng L, Blanca A, Baroni G, Minervini A, Lopez-Beltran A (2016) T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIalpha, survivin, and E-cadherin. Hum Pathol 57:78–84. https://doi.org/10.1016/j.humpath.2016.06.022 CrossRefPubMed

16.

Warrick JI, Sjodahl G, Kaag M, Raman JD, Merrill S, Shuman L, Chen G, Walter V, DeGraff DJ (2019) Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants. Eur Urol 75:18–22. https://doi.org/10.1016/j.eururo.2018.09.003 CrossRefPubMed

17.

Jawhar NM (2009) Tissue microarray: a rapidly evolving diagnostic and research tool. Ann Saudi Med 29:123–127CrossRefPubMedPubMedCentral

18.

Jakobsson L, Chebil G, Marzouka NA, Liedberg F, Sjodahl G (2018) Low frequency of intratumor heterogeneity in bladder cancer tissue microarrays. Bladder Cancer 4:327–337. https://doi.org/10.3233/blc-180176 CrossRefPubMedPubMedCentral

Title: Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder
Authors: Maria Del Carmen Rodriguez Pena
Alcides Chaux
Marie-Lisa Eich
Aline C. Tregnago
Diana Taheri
Walaa Borhan
Rajni Sharma
M. Katayoon Rezaei
George J. Netto
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keywords: Urothelial Cancer
Urothelial Cancer
Published in: Virchows Archiv / Issue 3/2019
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-019-02618-5

At a glance: The STEP trials

Springer Medicine

Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Disease heterogeneity in IgG4-related hypophysitis: report of two histopathologically proven cases and review of the literature

Spread through air spaces (STAS) is a predictor of poor outcome in atypical carcinoids of the lung

Spindle cell liposarcoma with a TRIO-TERT fusion transcript

Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study

Prognostic significance of histological categorization of desmoplastic reaction in colorectal liver metastases

Comparative genome-wide analysis of gastric adenocarcinomas with hyperplastic polyp components